Studie - Glomerulonephritis – Pipeline Review, H1 2012

Glomerulonephritis — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Glomerulonephritis - Pipeline Review, H1 2012', provides an overview of the Glomerulonephritis therapeutic pipeline. This report provides information on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glomerulonephritis. 'Glomerulonephritis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Glomerulonephritis.
- A review of the Glomerulonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Glomerulonephritis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Glomerulonephritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Glomerulonephritis Overview 7

Therapeutics Development 8

An Overview of Pipeline Products for Glomerulonephritis 8

Glomerulonephritis Therapeutics under Development by Companies 10

Glomerulonephritis Therapeutics under Investigation by Universities/Institutes 11

Late Stage Products 12

Comparative Analysis 12

Mid Clinical Stage Products 13

Comparative Analysis 13

Early Clinical Stage Products 14

Comparative Analysis 14

Pre-Clinical Stage Products 15

Comparative Analysis 15

Glomerulonephritis Therapeutics — Products under Development by Companies 16

Glomerulonephritis Therapeutics — Products under Investigation by Universities/Institutes 17

Companies Involved in Glomerulonephritis Therapeutics Development 18

Baxter International Inc. 18

Optherion, Inc. 19

Alexion Pharmaceuticals, Inc. 20

Pharmalink AB 21

Ferring Pharmaceuticals, Inc. 22

Glomerulonephritis — Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Combination Products 24

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 30

Nefecon - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Soliris - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Recombinant Protective Human CFH - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Tetracosactide Hexacetaat - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Aliskiren - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Rituximab - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Mycophenolate Mofetil + Irbesartan - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Pentoxifylline - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Rituximab + Abatacept - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Rituximab + Tocilizumab - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Myfortic + Prednisolone - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

MIF Inhibitors - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Ramipril - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Sirolimus + Enalapril + Atorvastatin - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Anti-MIF Antibody - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Glomerulonephritis Therapeutics — Drug Profile Updates 48

Glomerulonephritis Therapeutics — Discontinued Products 52

Glomerulonephritis Therapeutics - Dormant Products 53

Glomerulonephritis — Product Development Milestones 54

Featured News & Press Releases 54

Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 54

Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 54

Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 55

Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 55

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 58

Disclaimer 58





List of Tables

Number of Products Under Development for Glomerulonephritis, H1 2012 8

Products under Development for Glomerulonephritis — Comparative Analysis, H1 2012 9

Number of Products under Development by Companies, H1 2012 10

Number of Products under Investigation by Universities/Institutes, H1 2012 11

Comparative Analysis by Late Stage Development, H1 2012 12

Comparative Analysis by Mid Clinical Stage Development, H1 2012 13

Comparative Analysis by Early Clinical Stage Development, H1 2012 14

Comparative Analysis by Pre-Clinical Stage Development, H1 2012 15

Products under Development by Companies, H1 2012 16

Products under Investigation by Universities/Institutes, H1 2012 17

Baxter International Inc., H1 2012 18

Optherion, Inc., H1 2012 19

Alexion Pharmaceuticals, Inc., H1 2012 20

Pharmalink AB, H1 2012 21

Ferring Pharmaceuticals, Inc., H1 2012 22

Assessment by Monotherapy Products, H1 2012 23

Assessment by Combination Products, H1 2012 24

Assessment by Stage and Route of Administration, H1 2012 26

Assessment by Stage and Molecule Type, H1 2012 29

Glomerulonephritis Therapeutics — Drug Profile Updates 48

Glomerulonephritis Therapeutics — Discontinued Products 52

Glomerulonephritis Therapeutics — Dormant Products 53





List of Figures

Number of Products under Development for Glomerulonephritis, H1 2012 8

Products under Development for Glomerulonephritis — Comparative Analysis, H1 2012 9

Products under Development by Companies, H1 2012 10

Products under Investigation by Universities/Institutes, H1 2012 11

Late Stage Products, H1 2012 12

Mid Clinical Stage Products, H1 2012 13

Early Clinical Stage Products, H1 2012 14

Pre-Clinical Stage Products, H1 2012 15

Assessment by Monotherapy Products, H1 2012 23

Assessment by Combination Products, H1 2012 24

Assessment by Route of Administration, H1 2012 25

Assessment by Stage and Route of Administration, H1 2012 26

Assessment by Molecule Type, H1 2012 27

Assessment by Stage and Molecule Type, H1 2012 28

• Growth Hormone Deficiency – Pipeline Review, H1 2013
• Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013
• Growth Disorders – Pipeline Review, H1 2013
• Kidney Fibrosis – Pipeline Review, H1 2013
• Urinary Incontinence – Pipeline Review, H1 2013
• Global Endocrinology Drugs Market 2012-2016
• Inguinal Hernia Global Clinical Trials Review, H1, 2013
• End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2012
• Microalbuminuria – Pipeline Review, H2 2012
• Nocturia – Pipeline Review, H2 2012
• Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
• Hypoparathyroidism – Pipeline Review, H2 2012
• Proteinuria – Pipeline Review, H2 2012
• Thyroid Gland Disorders – Pipeline Review, H2 2012
• Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2012
• Hypothyroidism Global Clinical Trials Review, H2, 2012
• Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012
• Other Genito Urinary Disorders – Pipeline Review, H2 2012
• Urinary Retention Global Clinical Trials Review, H2, 2012
• Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H2 2012